BAM
ALLO icon

Blueshift Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Blueshift Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Buy
+14,901
New +$32.7K 0.01% 550
2022
Q2 		– Sell
-14,811
Closed -$135K – 661
2022
Q1 		$135K Buy
+14,811
New +$154K 0.01% 758
2021
Q2 		– Sell
-12,024
Closed -$424K – 901
2021
Q1 		$424K Buy
+12,024
New +$406K 0.04% 527

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Blueshift Asset Management's ALLO Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 14,901 shares worth $31K. The stake represents 0.01% of the portfolio and ranks #550 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in ALLO as recently as Q1 2022.

Blueshift Asset Management first reported a position in ALLO in Q1 2021 and has held it in 3 quarters since. The position peaked at $424K in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Blueshift Asset Management held 14,901 shares of Allogene Therapeutics worth $31K as of Q2 2026.
  • Allogene Therapeutics was a new Blueshift Asset Management position in Q2 2026.
  • Allogene Therapeutics made up 0.01% of Blueshift Asset Management's portfolio in Q2 2026, its #550 holding.
  • Blueshift Asset Management first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • Blueshift Asset Management's Allogene Therapeutics position peaked at $424K in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.